Methadone and neuropathic cancer pain subcomponents: a prospective cohort pilot study

Fawoubo, Audrey; Perceau-Chambard, Élise; Ruer, Murielle; Filbet, Marilène; Tricou, Colombe; Economos, Guillaume

doi:10.1136/bmjspcare-2021-003220

Cited by 5 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Finally, switching from another opioid to methadone-a MOR agonist and N-methyl-D-aspartate (NMDA) antagonist-has been shown to improve pain scores in patients with NCP in a recently published prospective cohort pilot study. Allodynia and the pressure/squeezing sensations were the most markedly reduced [75]. Methadone's complex pharmacokinetic profile-most notably its long half-life-and its variable conversion ratio when switching from another opioid complicate its use in clinical practice [29].…”

Section: The Problem Of Neuropathic Painmentioning

confidence: 99%

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

2023

View full text Add to dashboard Cite

Pain is frequently reported during cancer disease, and it still remains poorly controlled in 40% of patients. Recent developments in oncology have helped to better control pain. Targeted treatments may cure cancer disease and significantly increase survival. Therefore, a novel population of patients (cancer survivors) has emerged, also enduring chronic pain (27.6% moderate to severe pain). The present review discusses the different options currently available to manage pain in (former) cancer patients in light of progress made in the last decade. Major progress in the field includes the recent development of a chronic cancer pain taxonomy now included in the International Classification of Diseases (ICD-11) and the update of the WHO analgesic ladder. Until recently, cancer pain management has mostly relied on pharmacotherapy, with opioids being considered as the mainstay. The opioids crisis has prompted the reassessment of opioids use in cancer patients and survivors. This review focuses on the current utilization of opioids, the neuropathic pain component often neglected, and the techniques and non-pharmacological strategies available which help to personalize patient treatment. Cancer pain management is now closer to the management of chronic non-cancer pain, i.e., “an integrative and supportive pain care” aiming to improve patient’s quality of life.

show abstract

Section: The Problem Of Neuropathic Painmentioning

confidence: 99%

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

2023

View full text Add to dashboard Cite

show abstract

“…Finally, switching from another opioid to methadone-a MOR agonist and N-methyl-D-aspartate (NMDA) antagonist-has been shown to improve pain scores in patients with NCP in a recently published prospective cohort pilot study. Allodynia and the pressure/squeezing sensations were the most markedly reduced [61]. Methadone's complex pharmacokinetic profile-most notably its long half-life-complicates its use in clinical practice [28].…”

Section: The Problem Of Neuropathic Feature In Cancer Painmentioning

confidence: 99%

Cancer Pain Management - Current Concepts, Strategies and Management Techniques

Mestdagh¹,

Steyaert²,

Lavand’homme³

2023

Preprint

View full text Add to dashboard Cite

Pain is frequently reported during cancer disease, and still remains poorly controlled in 40% of patients. Recent developments in oncology have helped to better control pain. Targeted treatments may cure cancer disease and significantly increase survival. Thereby, a novel population of patients (cancer survivors) has emerged, also enduring chronic pain (27.6% moderate to severe pain). The present review discuss the different options currently available to manage pain in (former) cancer patients in the light of progress made in the last decade. Major progress in the field are recent development of a chronic cancer pain taxonomy now included in International Classification of Diseases (ICD-11) and update of WHO analgesic ladder. Until recently, cancer pain management has mostly relied on pharmacotherapy, opioids being considered as mainstay. The opioids crisis has prompted the reassessment of opioids use, both in cancer patients and cancer survivors. The review focuses on the current utilization of opioids, on the neuropathic pain component often neglected and on techniques and non-pharmacological strategies available which help to personalize patient’s treatment. Cancer pain management is now closer to the management of chronic non-cancer pain i.e. “an integrative pain care” aiming to improve patient’s quality of life.

show abstract

“…Methadone is a synthetic opioid-receptor agonist and N-methyl-D-aspartate (NMDA) inhibitor [50]. A recent prospective cohort pilot study on patients with NCP indicated that methadone could significantly improve neuropathic pain through a targeted effect on allodynia and the pressure/squeezing component [51]. Due to its unpredictable very long half-life and risk of accumulation and toxicity, its use should be reserved to experienced clinicians [11,26].…”

Section: Opioidsmentioning

confidence: 99%

Treatment of Neuropathic Pain Directly Due to Cancer: An Update

Shkodra

Caraceni

2022

Cancers

View full text Add to dashboard Cite

Neuropathic pain can be defined as pain related to abnormal somatosensory processing in either the peripheral or central nervous system. In this review article, with neuropathic cancer pain (NCP), we refer to pain due to nervous tissue lesions caused by the tumor or its metastases. Nervous tissue damage is the cause of cancer pain in approximately 40% of those experiencing cancer pain. Recognizing a neuropathic pathophysiology in these cases may be difficult and requires specific criteria that are not homogenously applied in clinical practice. The management of this type of pain can be challenging, requiring the use of specific non-opioid adjuvant drugs. The majority of the criteria for NCP diagnosis and management have been based mainly on results from the noncancer population, risking the failure of addressing the specific needs of this population of patients. In this review, we summarize current management options available for NCP and provide some insights on new promising treatments.

show abstract

Methadone and neuropathic cancer pain subcomponents: a prospective cohort pilot study

Cited by 5 publications

References 10 publications

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

Cancer Pain Management: A Narrative Review of Current Concepts, Strategies, and Techniques

Cancer Pain Management - Current Concepts, Strategies and Management Techniques

Treatment of Neuropathic Pain Directly Due to Cancer: An Update

Contact Info

Product

Resources

About